Correction to: Alendronate use and bone mineral density gains in women with moderate-severe (stages 3B-5) chronic kidney disease: an open cohort multivariable and propensity score analysis from Funen, Denmark
1 Faculty of Epidemiology and Population Health, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
2 Center for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
3 Department of Public Health, Saint Paul Hospital Millennium Medical College, Addis Ababa, Ethiopia.
4 OPEN, Department of Health, University of Southern Denmark, Odense, Denmark.
5 Department of Public Health, Clinical Pharmacology and Pharmacy, University of Southern Denmark, Odense, Denmark.
6 Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
7 Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
8 MRC Lifecourse Epidemiology Unit, Southampton, UK.
9 Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark.
10 Department of Endocrinology, Odense University Hospital, Odense, Denmark.
11 Center for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. daniel.prietoalhambra@ndorms.ox.ac.uk.
12 MRC Lifecourse Epidemiology Unit, Southampton, UK. daniel.prietoalhambra@ndorms.ox.ac.uk.
13 GREMPAL Research Group (Idiap Jordi Gol Primary Care Research Institute) and CIBERFes, Universitat Autonoma de Barcelona, Barcelona, Spain. daniel.prietoalhambra@ndorms.ox.ac.uk.